{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:22:43Z","timestamp":1761920563718},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Research Committee of Prion Disease"},{"name":"Research on Policy Planning"},{"name":"Evaluation for Rare and Intractable Diseases"},{"name":"Health and Labour Sciences Research Grants"},{"name":"The Ministry of Health, Labour and Welfare, Japan"}],"content-domain":{"domain":["clinicalkey.jp","jocn-journal.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.jocn.2019.01.034","type":"journal-article","created":{"date-parts":[[2019,2,14]],"date-time":"2019-02-14T05:09:14Z","timestamp":1550120954000},"page":"91-94","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Effect of dosage reduction on peripheral blood lymphocyte count in patients with multiple sclerosis receiving long-term fingolimod therapy"],"prefix":"10.1016","volume":"63","author":[{"given":"Kazuya","family":"Takahashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jocn.2019.01.034_b0005","unstructured":"FDA Drug Safety Communication: FDA warns about cases of rare brain infection with MS drug Gilenya (fingolimod) in two patients with no prior exposure to immunosuppressant drugs, http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm456919.htm; 2015 [accessed 4 August 2018]."},{"key":"10.1016\/j.jocn.2019.01.034_b0010","doi-asserted-by":"crossref","first-page":"e1815","DOI":"10.1212\/WNL.0000000000005529","article-title":"Progressive multifocal leukoencephalopathy after fingolimod treatment","volume":"90","author":"Berger","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2019.01.034_b0015","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/ene.12304","article-title":"Anti-JC virus (JCV) antibody prevalence in the JCV Epidemiology in MS (JEMS) trial","volume":"21","author":"Bozic","year":"2014","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.jocn.2019.01.034_b0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0174005","article-title":"Stability and predictive value of anti-JCV antibody index in multiple sclerosis: a 6-year longitudinal study","volume":"12","author":"Hegen","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jocn.2019.01.034_b0025","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1007\/s00415-018-8813-z","article-title":"Serum anti-JCV antibody indexes in Japanese patients with multiple sclerosis: elevations along with fingolimod treatment duration","volume":"265","author":"Aoyama","year":"2018","journal-title":"J Neurol"},{"key":"10.1016\/j.jocn.2019.01.034_b0030","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1212\/01.wnl.0000435564.92609.2c","article-title":"Basis for fluctuations in lymphocyte counts in fingolimod-treated patients with multiple sclerosis","volume":"81","author":"Henault","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2019.01.034_b0035","doi-asserted-by":"crossref","first-page":"354","DOI":"10.5114\/ceji.2015.54599","article-title":"Influence of fingolimod on basic lymphocyte subsets frequencies in the peripheral blood of multiple sclerosis patients - preliminary study","volume":"40","author":"Rudnicka","year":"2015","journal-title":"Cent Eur J Immunol"},{"key":"10.1016\/j.jocn.2019.01.034_b0040","article-title":"Peripheral blood T cell dynamics predict relapse in multiple sclerosis patients on fingolimod","volume":"10","author":"Song","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jocn.2019.01.034_b0045","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12883-017-0794-5","article-title":"Long-term efficacy and safety of fingolimod in Japanese patients with relapsing multiple sclerosis: 3-year results of the phase 2 extension study","volume":"17","author":"Saida","year":"2017","journal-title":"BMC Neurol"},{"key":"10.1016\/j.jocn.2019.01.034_b0050","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/cen3.12397","article-title":"Neurological safety of fingolimod: an updated review","volume":"8","author":"Yoshii","year":"2017","journal-title":"Clin Exp Neuroimmunol"},{"key":"10.1016\/j.jocn.2019.01.034_b0055","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1177\/1352458517713147","article-title":"Reconstitution of the peripheral immune repertoire following withdrawal of fingolimod","volume":"23","author":"Ghadiri","year":"2017","journal-title":"Mult Scler"},{"key":"10.1016\/j.jocn.2019.01.034_b0060","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1177\/1352458517694089","article-title":"Half-dose fingolimod for treating relapsing-remitting multiple sclerosis: observational study","volume":"24","author":"Zecca","year":"2018","journal-title":"Mult Scler"},{"key":"10.1016\/j.jocn.2019.01.034_b0065","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1177\/1352458517722647","article-title":"Intermittent drug holidays in fingolimod therapy for multiple sclerosis","volume":"24","author":"Tanaka","year":"2018","journal-title":"Mult Scler"},{"key":"10.1016\/j.jocn.2019.01.034_b0070","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jneuroim.2015.09.002","article-title":"Daily fingolimod administration may cause lymphopenia but alternate-day administration may be too little to inhibit disease activity","volume":"288","author":"Tanaka","year":"2015","journal-title":"J Neuroimmunol"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586818314309?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586818314309?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,11]],"date-time":"2019-04-11T21:18:55Z","timestamp":1555017535000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586818314309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":14,"alternative-id":["S0967586818314309"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2019.01.034","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of dosage reduction on peripheral blood lymphocyte count in patients with multiple sclerosis receiving long-term fingolimod therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2019.01.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}